Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
Infect Dis Ther
.
2022 Feb;11(1):127.
doi: 10.1007/s40121-021-00583-8.
Authors
Yiling Jiang
1
,
Eric M Sarpong
2
,
Pamela Sears
2
,
Engels N Obi
2
Affiliations
1
Merck Sharp & Dohme (UK) Ltd., 120 Moorgate, London, EC2Y 9AL, UK. yiling.jiang1@msd.com.
2
Merck & Co., Inc., 200 Galloping Hill Road, Kenilworth, NJ, 07033, USA.
PMID:
35034290
PMCID:
PMC8847657
DOI:
10.1007/s40121-021-00583-8
No abstract available
Publication types
Published Erratum